In Part 1 of this ongoing 12-part COVID-19 series, listen to a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data on evidence-based antiviral therapy for severe disease followed by answers to critical clinician questions on COVID-19 transmission, diagnosis, and management from frontline provider Vikramjit Mukherjee, MD.
In this episode, Part 1 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data from the ACTT-1 trial comparing remdesivir vs placebo for severe COVID-19 treatment. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter:
Vikramjit Mukherjee, MD
Director, Medical Intensive Care Unit
Bellevue Hospital
Assistant Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
NYU School of Medicine
New York, New York
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program: